New York, U.S. – Johnson & Johnson has announced plans to invest more than $55 billion in the United States over the next four years, marking a 25% increase in domestic investment compared to the previous term. The move underscores the company’s commitment to expanding its manufacturing and research capabilities in the country.
Major Expansion Plans
The pharmaceutical and healthcare giant revealed on Friday that the investment will include the construction of four new manufacturing plants, with the first high-tech facility being built in Wilson, North Carolina, located just east of Raleigh. The company has yet to disclose the locations of the other three planned facilities.
Johnson & Johnson also intends to expand several existing manufacturing sites and enhance its research and development infrastructure. According to company estimates, the economic impact of this investment could exceed $100 billion annually.
Commitment to U.S. Manufacturing
Chairman and CEO Joaquin Duato emphasized the importance of this expansion, stating, “Our increased U.S. investment begins with the groundbreaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but also manufacture cutting-edge medicines to treat patients in America and around the world.”
This announcement aligns with a broader trend of multinational corporations increasing their manufacturing presence in the United States, amid economic policies encouraging domestic investment.
Industry-Wide Trend
Johnson & Johnson’s expansion follows similar commitments from major global companies. Earlier this month, Taiwan Semiconductor Manufacturing Co. (TSMC) pledged an additional $100 billion investment in the U.S., on top of the $65 billion already announced. Likewise, Apple recently disclosed plans to invest over $500 billion in the U.S. over the next four years, including a new server factory in Houston, Texas, which is expected to open in 2026.
Looking Ahead
With its ambitious investment plans, Johnson & Johnson is positioning itself as a leader in U.S.-based pharmaceutical and healthcare manufacturing. The company’s efforts are expected to create new jobs, enhance technological advancements, and strengthen domestic production capabilities in the coming years.
Further details on the remaining three manufacturing plants and specific research initiatives are anticipated as Johnson & Johnson progresses with its expansion strategy.
